Drug profile · INN
tacrolimus
ADVAGRAF XL
tacrolimus (ADVAGRAF XL) is a fk506-binding protein 1a inhibitor. Associated with Alphapharm Pty Ltd. Route of administration: topical. Current US regulatory status: approved.
Drug details — tacrolimus
- US status
- approved
- Class
- Dermatologicals (D11)
- Route
- TOPICAL
- Patents
- 4
- Programs
- 46
- Data quality
- 0.89
Quick answer
tacrolimus (ADVAGRAF XL) is a fk506-binding protein 1a inhibitor. Associated with Alphapharm Pty Ltd. Route of administration: topical. Current US regulatory status: approved.
Key facts
Mechanism of action
FK506-binding protein 1A inhibitor
Primary target: Peptidyl-prolyl cis-trans isomerase FKBP1A
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
| NMPA | clinical trials | — |
Pipeline programs
Related & competitor drugs
Related patents
-
US 20260108463
NANOEMULSION FORMULATION WITH IMPROVED TACROLIMUS STABILITY AND SKIN PENETRATION
granted -
US 11291657
Methods of treating inflammatory bowel disease with AMD3100 and Tacrolimus
granted -
US 10420751
Methods of treating inflammatory bowel disease with AMD3100 and tacrolimus
granted -
US 6187745
Method of preventing nephrotoxicity caused by cyclosporins and tacrolimus
expired
Frequently asked questions
What is tacrolimus?
tacrolimus (ADVAGRAF XL) is a fk506-binding protein 1a inhibitor. Associated with Alphapharm Pty Ltd. Route of administration: topical. Current US regulatory status: approved.
What is the brand name for tacrolimus?
ADVAGRAF XL is a marketed brand name for tacrolimus. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of tacrolimus?
tacrolimus has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.